Most Recent Articles by James G. Dickinson
Expect major changes in the way the FDA does business with drug companies after the Trump administration takes over in January.
That change is coming about in the wake of a string of First Amendment-based losses for the FDA in federal courts around the country.
Would you expect that patient power exerted through social media might shake the job of a high-level FDA center director?
The FDA has to respect First Amendment limitations regulating scientific communication
Medtronic, as part of the settlement, will pay $602,000 to a whistleblower to settle charges it caused physicians to submit false claims to federal health programs.
More Articles by James G. Dickinson
- Top 25 rare disease brands, by sales
- Five things for pharma marketers to know: Monday, February 13, 2016
- Orphan drugs face criticism on prices — and from patients
- Five things for pharma marketers to know: Thursday, February 16, 2017
- Five things for pharma marketers to know: Wednesday, February 15, 2017